Sorrento Therapeutics, Inc.
SRNE
$0.0009
-$0.0001-10.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 31.10% | -11.61% | 19.26% | 44.25% | -15.17% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.10% | -11.61% | 19.26% | 44.25% | -15.17% |
| Cost of Revenue | -22.98% | -29.75% | -12.05% | 44.33% | -6.00% |
| Gross Profit | 37.49% | 36.24% | 20.38% | -44.35% | 3.19% |
| SG&A Expenses | 1.67% | 24.03% | -27.83% | 3.44% | -4.29% |
| Depreciation & Amortization | 8.89% | 8.99% | 9.08% | 12.70% | -3.27% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.18% | -8.69% | -19.18% | 24.65% | -5.18% |
| Operating Income | 16.45% | 8.13% | 23.97% | -22.03% | 3.77% |
| Income Before Tax | 51.09% | -266.35% | -28.67% | 23.38% | -31.78% |
| Income Tax Expenses | 163.90% | 683.87% | 94.51% | -362.95% | -63.81% |
| Earnings from Continuing Operations | 50.55% | -281.42% | -56.78% | 24.48% | -31.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,755.71% | 5,558.18% | 668.99% | 446.35% | 754.76% |
| Net Income | 56.48% | -242.07% | -54.89% | 25.23% | -31.30% |
| EBIT | 16.45% | 8.13% | 23.97% | -22.03% | 3.77% |
| EBITDA | 17.45% | 8.77% | 25.12% | -23.14% | 4.00% |
| EPS Basic | 68.20% | -112.30% | 1.22% | 50.46% | 5.47% |
| Normalized Basic EPS | 53.06% | 54.63% | 45.38% | 24.42% | 28.52% |
| EPS Diluted | 68.20% | -114.70% | 0.81% | 50.04% | 5.47% |
| Normalized Diluted EPS | 53.06% | 54.63% | 45.38% | 24.42% | 28.52% |
| Average Basic Shares Outstanding | 36.86% | 61.11% | 56.78% | 50.90% | 38.90% |
| Average Diluted Shares Outstanding | 36.86% | 61.11% | 56.78% | 50.90% | 38.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |